* Note: Prices are in Million (M) USD.
Description:
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $1,214 M
Debt : $604 M
EBITDA : $883 M
Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 11.54
Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 20 overlapping fiscal years (max 20).Average Free Cash Flow: $-67 M
Average Revenue: $1,053 M
Revenue Converted To Free Cash Flow (%): -6.4%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $2,854 M
Revenue 4 Years Ago (2020-12-31): $1,860 M
Last 5 Years Average Revenue Growth: 11%
Since Revenue Growth is between 10 - 15, 3 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $197 M
Share Count 5 Years Ago (2020-12-31): $192 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $5.60
Trailing 12-Month Earnings Per Share (EPS): $4.50
Average Earnings Per Share (EPS): $5.05
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 19 valid ROE years (max 20).Average ROE: -2.0%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $58
52-Week Low: $53
Threshold Price (15% Above 52-Week Low): $61
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $11,049 M
Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 25 points to above Biomarin Pharmaceutical Inc (BMRN) stock.
Last 3 Years Avg PE 20.53, Fair Value PE 25, Industry Based PE 20, Growth Based PE 10, RCFC Based PE 12, ROE Based PE 10, Risk-Free Anchored PE (25% MoS) 17.08. Based on these 7 values, average assigned is 16.37. Value-Trades has assined P/E value 16.37. Since an average (Current Year EPS + Next Year EPS) earning per share is $5.05.
The fair value of Biomarin Pharmaceutical Inc (BMRN) stock should be (16.37 x $5.05) = $82.69.
